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PURPOSE 
Since the discovery that 5-hydroxytryptamine (’’Serotonin" 
or 5-HT) occurs naturally in significant amounts in brain tissue* 
evidence has accumulated from many investigations to suggest that 
it may play a role in neural functioning. Of particular interest 
has been the observation that lysergic acid diethylamide (LSD-25)* 
a substance known to produce hallucinatory effects in man* strongly 
antagonizes the pharmacological actions of 5-hydroxytryptamine (5-HT) 
on a number of peripheral tissues® Some workers have postulated 
that the psychotomimetic actions of LSD-25 nay be mediated through 
a central antagonism of 5-HT. Intensive studies up to the present 
time* however* have failed to define clearly the neuropharmacolo- 
gical interactions between LSD-25 and 5-hy droxytryptamine (5-HT), 
Profound alterations in brain levels of 5-HT have been 
•shown to follow the administration of certain drugs (reserpine* 
iproniazid* and 5-hydroxytryptophan)* which affect mental processes. 
These agents also have certain structural and pharmacologic relation¬ 
ships in common with 5-HT, These findings suggest the possibility 
that similar changes in brain 5-HT may occur with LSD-25—particularly 
if a central interaction between LSD-25 and 5-HT takes place. In 
earlier reports in the literature* 5-HT levels in rat brains were 
found to be unaltered four hours following a single injection of 
LSD-25 * These investigations* however* failed to account for changes 
in 5-HT brain levels which might be detectable at shorter or longer 
periods following LSD-25 administration, Moreover* the possibility 
of changes in 5-HT distribution in specific brain areas was not 
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explored. The measurement of 5-UT brain levels following chronic 
administration of LSD-25 has not been reported although unpublished 
data in this laboratory showed variably increased levels of 5-UT 
in the brains of rats rendered tolerant to the mental effects of 
LSD-25 by repeated daily injections. 
The present work has been undertaken to study the general 
problem of the central interaction between LSD-25 and 5-UT by fur¬ 
thering the measurements of previous investigators of brain levels 
of 5-UT following acute and chronic administration of LSD-25. Using 
this technique, the contention that the central actions of LSD-25 
are mediated through its interaction with 5-UT, might- be supported 
by the detection of alteration of 5-UT levels following single doses 
of LSD-25. The finding of changes in 5-UT brain level only after 
chronic administration of LSD-25 would suggest that the tolerance, 
v/hich occurs to certain action 25 on repeated administration, 
might be related to a central interaction between the two compounds. 
The investigation will be limited specifically to the following: 
1. The determination of serotonin (5-HT) content in whole rat brains 
at varying time intervals following a single injection of LSD-25* 
2. The determination of 5-UT levels in whole brains of rats ren¬ 
dered partially or completely tolerant to LSD-25—ten minutes and 
twenty-four hours following the last injection of LSD-25. 
3. The determination of 5-HT levels in certain discreet areas of 
the dog1s brain following acute and chronic administration of LSD-25. 
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HISTORICAL BACKGROUND 
I, 5-Hydroxytryptamine and the Nervous System: 
5-Hydroxytryptamine (5-HT) was first isolated from natural 
sources and identified only a few years ago through the independent 
1,21 
investigations of Rapport et al. and Srspamer et al* Subsequently 
3/ 
it has been found to have widespread occurrence in nature. In 
vertebrates, 5-HT is present in significant Quantities in the gas- 
2/ 
trointestinal mucosa, platelets, spleen and nervous tissue* Many 
pharmacological properties have been described for 5-HT and are 
3/ 4,5/ 
reviewed at length by Erspamer and Page. Of these pharmacolo¬ 
gical actions of 5-HT, stimulation of certain smooth muscle is the 
most characteristic. 7 
Owing to its widespread distribution and high pharmacolo¬ 
gical activity, 5-hydroxytryptamine has evoked a great deal of study 
and speculation as to its biologic significance. It was postulated 
by early workers that 5-HT acted to (l) influence hemostasis, (2) 
control vascular tone and (3) participate in the regulation bf the 
3/ 
function of the kidney* The hypothesis was then proposed in 1953 
6/ 7,3/ 
by Gaddum and in 1954 by Woolley and Shaw that 5-HT parti¬ 
cipates actively in the physiology of the nervous system. Though 
its precise role is at present uncertain, much experimental evidence 
in recent years supports the latter postulate, 5-HT has been shown 
to possess many of the properties which one would attribute to a 
substance partaking in neural functioning. This evidence, which 
will be discussed in detail, consists briefly of the following: 
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(A) 5-HT occurs in significant amounts in the nervous system; (B) 
Enzymes for the synthesis and destruction of 5-HT are also present 
in the nervous system; (C) 5-HT has direct actions on neural func¬ 
tioning: (D) 5-HT may be released during nervous activity; (E) Some 
compounds having actions on the nervous system are biochemically or 
pharmacologically related to 5-HT and may possibly act through 5-HT» 
A, Occurrence of 5-HT in the Nervous System: 5-Hydroxytryptsmine 
9/ 
was first demonstrated in brain extracts by Twarog and Page in 
10/ 
1953 and its presence was confirmed by Zetler and Schlosser in 1954. 
These workers utilized an acetone extraction procedure and bioassay 
11/ 
with the heart of Venus mercenaria.. Subsequently, Amin et al* 
12/ 
and Paasonen and Vogt made the interesting observation that 5-HT 
is not equally distributed in the brain of the dog but discreetly 
localized in certain brain structures. The highest concentrations 
of 5-HT were found in brain nuclei associated with autonomic function— 
the hypothalamus, midbrain and medulla, and in the area postrema, 
while no detectable amounts were present in neo-cortical areas or 
medullary nerve 'fibers. The general pattern of distribution of 5-HT 
n/ 
was noted to parallel that found by Vogt for nor-epinephrine. 
Paasonen, McLean and Giarraan showed that certain limbic cortical 
structures—the medial and lateral pyriform cortex, the entorhinal 
cortex and hippocampus also contain appreciable concentrations of 
14/ 
5-HT, More recently, Udenfriend et al. were able to determine 
5-HT brain levels by direct measurement, using a flourometric assay 
15-19/ 
and butanol extraction Their results revealed a pattern of 
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distribution of 5-HT resembling those of previous investigators. 
The ubiquity of 5-HT in the nervous system was demonstrated by its 
detection in certain peripheral autonomic ganglia by Florey and 
20/ 21/ 22/ 
Florey, Gertner et al. and 'Jelsh. 
B, Occurrence of Gnzymes for the Synthesis and Destruction of 5-HT 
in the Nervous System: The synthesis of 5-UT has been shev.m to 
procede from tryptophan and to depend upon two enzymes—tryptophan 
23 ?L / 
oxidase and 5-hydr0x3d:ryptophan decarboxylase. Tryptophan 
is converted to 5-hydroxytryptophan in the presence of tryptophan 
oxidase. Though this enzyme has been studied only in microorganisms, 
its apparent absence is animal tissues has been explained by Udenfriend 
et al. to result from the fact that the above reaction constitutes 
2H 
the rate limiting step in the synthesis. The second, enzyme, 
5-hydrcxytryptophan decarboxylase, specifically catalyzes the 
21-26/ 
decarboxylation of 5-hydr oxyt rypt ophan to 5-hydr oxyt rypt amine. 
5-Hydroxyt ryptophan decarboxylase has been detected in homogenates 
of a number of mammalian tissues including nervous tissue by Gaddum 
27/ 17.19/ 
and Giarman and by Udenfriend et al. The data of the above 
workers indicate that 5-hydroxytryptophan decarboxlase has a distri¬ 
bution in the dog1s nervous system which parallels, in general, that 
of 5-HT with the exception of the area postrema which contains 
relatively small amounts of the enzyme, and the sympathetic ganglia 
which have relatively high decarboxylase activity. The experiments 
of Bogdanski, Weissbacl and Udenfriend further emphasize the impor- 
28-31/ 
tant activity of 5-hydroxytryptophan decarboxylase in the brain. 
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They noted that 5-HT produced in the periphery failed to reach the 
brain because of its destruction in the blood by monoamine oxidase 
and its failure to penetrate the blood-brain barrier. They were 
able, however, to produce brain levels of 5-HT several tines higher 
than normal following peripheral injections of 5-hydroxytryptophan• 
This precursor of 5-HT readily gained access to the brain and was 
decarboxylated. 
Of the numerous possible pathways for the destruction of 
5-HT, its oxidation to 5-hydroxyindoleacetic acid is probably the 
r> to 00/ 
- 
most important. Monoamine oxidase, the enzyme which catalyses 
16-19/ 
this reaction, has been clearly demonstrated in brain tissue. 
Unlike 5-HT, however, it has been found to be relatively cvenl’ 
19/ 
distributed throughout the brain. Of note is the demonstration 
that the administration of iproniazid ("Marsalid1’)> a monoamine 
oxidase inhibitor, causes significant elevations of 5-HT brain 
34.35/ 
levels. 
C. Action of 5-hydroxytryptamine (5-HT) on Neural Functioning: 
Many different techniques of direct and indirect administration 
have been employed to study the central actions of 5-HT because of 
the difficulty in obtaining pharmacological levels in the brain 
following parenteral injection. On the other hand, certain methods 
of study have lended themselves to the use of peripheral 5-HT 
administration. Shore et al. obtained indirect evidence of the 
central actions of 5-HT using intraperitoneal injections in mice 
They observed that 5-HT had a striking central potentiating action 
on certain hypnotics. In electrophysiological experiments, Marrazzi 
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et al. observed marked cerebral synaptic inhibition in the transcallosal 
pathway of the visual system of the cat following intracarotid injec- 
38-10/ 
tions of 5-HT. Similarly, Everts et al. noted that bufotenine, 
a 5-HT analog, produced inhibition of the nostsynaptic spike in the 
41/ 
lateral geniculate nucleus. 5-HT exerted variable effects on the 
spinal reflexes of the cat following intravenous administration ac- 
42,43/ 
cording to the work of von Weidmann and Cerletti. 
Using the technique of peripheral injection of 5-hydroxy- 
tryptophan, as previously described, Bogdanski et al. were able to 
28-31/ 
produce high brain concentrations of 5-KT and observe their effects. 
Small doses of 5-hydroxytryptophan produced sedation while high doses 
were accompanied by excitement, muscle tremors, loss of placing re¬ 
actions, loss of response to visual stimulation, and various autonomic 
effects resembling those produced by LSD-25. These effects were seen 
to correspond to 5-HT levels in the brain and were presumed, therefore, 
to be due to the 5-HT formed from 5-hydroxytryptophan rather than to 
5-hydroxytryptophan itself. 
Several workers have studied the effects of intraventricular 
injections of 5-HT. By the use of a permanently implanted cannula in 
a lateral ventricle of the cat, as originally introduced by Feldberg 
and Sherwood, the observation of conscious behavior folloxcLng the 
44/ . 
introduction of 5-HT has been possible. in these studies, 75-500 
micrograms of 5-HT have been followed in most instances by signs of 
45-47/ 
depression in animals. Vogt et al. observed that intraventricular 
injections of 5-HT produced low voltage slow activity in the spontaneous 
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E.E.G. of most of the brain areas studied, although long bursts of 
46/ 
high amplitude were noted in the reticular formation. 
In anatomical studies, human and rat oligodendroglia were 
48/ 
observed in tissue culture to contract in response to 5-HT. On this 
basis, Woolley and Shaw postulated that 5-HT might be responsible for 
rhythmic contractions of these cells, and thus play a role in promoting 
48/ 
intracerebral circulation. 
D. Release of 5-HT during Nervous Activity: Taylor, Corcoran and 
Page in 1951 provided some evidence that 5-HT might be released follow- 
49/ 
ing nervous stimulation. Using crossed circulation experiments, 
they demonstrated the release of a vasopressor substance following 
central vagal stimulation in spinal dogs. The vasopressor effect was 
unaffected by various blocking agents but was inhibited by 1-hydra- 
zinopthalazine, a compound which had previously been shown to inhibit 
the pressor action of 5-HT. 
Welsh showed that 5-HT excited the molluscan heart in the 
same manner as stimulation of the visceral ganglion following blockade 
22,50/ 
of the cholinergic inhibitor nerves. Agents that blocked 5-HT 
also abolished nervous excitation of the heart, suggesting that 5-HT 
or closely related substance might be released from the nerve endings. 
In preliminary experiments with perfused spinal cord of the 
frog, Angelucci discovered a release of active substances during the 
51/ 
course of reflex activity. Though not confirmed, one of the sub¬ 
stances in the perfusion fluid resembled 5-HT, 
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E. Effects of Other Drugs Related to Serotonin (5 —HT); Brodie and 
his co-workers in 1955 made one of the most interesting discoveries in 
the recent work with 5-HT. Thejr observed that the tranquilizing 
agent, reserpine, was capable of releasing 5-HT from its binding 
52-53/ 
sites in the brain and other body stores in experimental animals. 
Following an injection of 5 mg./kg. of reserpine, the brain levels of 
5-HT declined rapidly such that the release was almost complete in 
eight hours. Low brain levels of reserpine remained for twenty-four 
hours and then gradually increased to normal values over the next 
seven days. During the period in which the brain content of 5-HT was 
low, 5-hydroxyindoleacetic acid, a metabolic product of 5-HT, was 
excreted in large amounts in the urine. Hess, Shore and Brodie further 
demonstrated that the pharmacological effects of reserpine persisted 
54/ 
long after it was no longer detectable in the brain. These considera¬ 
tions and the finding of similar potentiating actions of 5-HT and re¬ 
serpine on hexobarbital anesthesia prompted Brodie et al. to postulate 
that reserpine exerted its central actions through the release of 
^ 53-58/ _ 
5-HT. In this regard, the persistence of relatively large amounts 
of 5-HT in the unbound form rather than the depletion of the total 
brain content of 5-HT, was considered responsible for the effects of 
reserpine. The above hypothesis was further strengthened by the find¬ 
ing that serotonin-releasing activity was limited to rauwolfia alkaloids 
(reserpine, deseroidine, and rescinnamine) which have tranquilizing 
58/ 
actions. The situation has been complicated, however, by the recent 
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discovery of nor-epineohrine release from the brain following reserpine 
12/ 
administration. High concentrations of unbound serotonin (5-HT), 
as produced by iproniazid or 5-hydroxylryptophan injections, have 
31,34/ 
been shorn to result in excited behavior rather than sedation. 
This inconsistency with Brodie’s hypothesis may be explained, on the 
other hand, by the assumption that 5-HT is self-inhibitory in high 
12/ 
concentrations» 
It has been suggested that other drugs may exert their 
6-8/ 
actions on the nervous system through their antagonism with 5-HT. 
Woolley and Shaw noted that a number of drugs, structurally related to 
5-HT and pharmacologica.lly antagonistic to its action on smooth muscle, 
7-8/ 
produced mental symptoms. (See Fig, l) They classified these anti¬ 
metabolites of 5-HT into three groups: (l) The harmala alkaloids, 
certain of which produce hallucinations and profound behavioral changes 
(2) The ergot alkaloids, including the potent hallucinogenic agent, 
lysergic acid diethylamide (LSB-25); and (3) Yohimbine, an aphrodisiac. 
Woolley and Shaw went on to postulate that 5-HT may be required for 
normal mental functioning and that mental abberations produced by 
drugs and naturally occurring psycoses may result from a relative 5-HT 
deficiency. Against this general theory is the strong evidence that 
(l) not all compounds antagonistic and structurally related to 5-HT 
produce mental disturbances and that (2) peripheral administration of 
5-KT does not correct such disturbances. Further consideration of the 
postulate of Woolley and Shaw as it regards lysergic acid diethylamide 
(LSD-25) will take place in later pages. 
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FIGURE 1 
STRUCTURAL FORMULAE OF SEROTONIN AND RELATED COMPOUNDS 
H CH C-t^-CH CH 
3 2 0=c 23 
5 HYDROXYTRYP FAMINE LYSERGIC ACID DIETHYLAMIDE 
HARMINE YOHIMBINE 
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II. Lysergic Acid Diethylamide, its Properties, and Relationship 
to 5-HT 
Although lysergic acid diethylamide (LSD-25) was first 
sjmthesized in 1938, its significance as a psychotogen was not rea¬ 
lized until 1943 when Hoffmann accidentally discovered, its hallucin- 
60/ 
ogenic properties. Stoll subsequently studied the psychiatric 
61/ 
effects of LSD-25 in a number of normal and schizophrenic subjects. 
The compound, in doses as small as 20—30 micrograms, was observed 
to produce a state of intoxication of the acute exogenic reaction 
61/ 
type, in which optic hallucinations and distortions were prominent. 
These clinical observations have been confirmed by numerous investi¬ 
ng/ §£/ 
gators and recently reviewed by Hoch and Koelle. Aside from 
its actions on mental processes, LSD-25 exerts many actions on the 
autonomic nervous system and certain peripheral structures. These 
pharmacological properties have been considered in the reviews of 
'64-65 / 
Rothlin and Cerletti and are summarized in Figure 2. 
Of the autonomic actions of LSD-25, its pyretogenic property 
has received considerable interest. Horita and Dille showed that the 
rectal temperature in rabbits, dogs, and cats rose significantly 
66/ 
following intravenous LSD-25 in a dose of 50 micrograms/kilogram. 
In rabbits the effect was maximal at the end of 1-2 hours but persisted 
66- 67/ 
6-8 hours. Experiments using pharmacological techniques and 
sectioning of the brain at different levels have suggested that the 
LSD-25 hyperpyrexia is mediated through a central diencephalic site 
67- 68/ 
of action. 
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FIGURE 2 
THE PHARMACOLOGICAL PROPERTIES OF 
LYSERGIC ACID DIETHYLAMIDE (LSD-25)* 
SOMATO-MOTOR FUNCTIONS 
Pyramidal and Extrapyramidal Effects 
Ataxia and Spastic Paralysis 
PSYCHIC FUNCTIONS AUTONOMIC NERVOUS FUNCTIONS 
Excitation 
Mood Changes 
Disturbances of Perception 
Depersonalization 
Schizophrenic State 
Mesodiencephalic Effects 
Mydriasis 
Tachycardia 
Hyperpyrexia 
Hyp erglyc end a 
Pilomotor Reaction 
Medullary or Bulbar Effects 
Lowering of the Blood Pressure 
Bradycardia 
Respiratory Depression 
DIRECT PERIPHERAL ACTIONS 
Inhibition of 5-HT on Different 
Organs in Vitro and in Vivo 
Uterus 
Blood Vessels Artificially Perfused 
Bronchial Musculature in High Doses 
Blood Vessels of the Spinal Cat 
Adrenolytic Action on Isolated Uterus and 
Seminal Vesicle 
* Adapted from Rothlin, E.: Pharmacology of lysergic acid diethyl¬ 
amide (LSD) and some of its related compounds. J. of Pharmacy and 
Pharmacology, 9: 1957• 
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The phenomenon of tolerance has been repeatedly observed 
in regard, to several actions of LSD-25 following repeated administra¬ 
tion of the compound. Stoll first described the development of toler- 
61/ 
ance to the psychic actions of LSD-25 in schizophrenic patients. 
More recently, tolerance to the hallucinatory actions in normal subjects 
and to the behavioral changes in schizophrenic patients has been 
observed to develop within four or five days with daily administration 
69-73/ 
of LSD-25. Similarly, tolerance has been observed with LSD-25 
74-76/ 
induced behavioral aberations in animals. Gogerty and Dille 
7U 
described tolerance to the pyretogenic effects of LSD-25 in rabbits. 
Of note has been the observation that rats do not develop tolerance 
75/ 
to LSD-25-induced bradycardia. 
6/ 
Owing to the stimulus of the suggestion of Gaddum, and 
7*8/ 
Woolley and Shaw that LSD-25 might exert its central actions through 
an antagonism of 5-HT, considerable study of the interactions of 5-HT 
and LSD-25 has taken place. Regarding peripheral sites of action, 
Gaddum has shown that LSD-25 in very small doses exerts a specific 
antagonism to the action of 5-HT on the rat uterus. LSD-25 has 
also been noted to antagonize the vasodilating action of 5-HT on the 
79-80/ 
perfused rabbit ear. Gaddum and Hameed observed little anta¬ 
gonism between LSD-25 and 5-HT in experiments on guinea pig ileum but 
pointed out that a different type of tryptamine receptor in the auto- 
I 
nomic ganglia of the intestine would account for the apparent lack of 
80/ 
interaction. On the other hand, some investigators, notably 
81/ 82/ 
Woolley and Shaw and Welsh and McCoy, have observed similarities 
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in the actions of LSD-25 and 5-HT on certain peripheral structures. 
At the present time, the relationships between LSD-25 and 
5-HT regarding their actions on the central nervous system are not 
clear. The hypothesis of Woolley and Shaw received some support in 
the studies of Shore et al. demonstrating the potent antagonistic 
action of LSD-25 on the potentiation of hexobarbital hypnosis in mice 
36-37/ 
by 5-HT. However, considerable evidence has accumulated to 
indicate that the peripheral antagonism of certain actions of 5-HT 
by LSD-25, does not by itself, explain the central effects of LSD-25. 
Rothlin and Cerletti have pointed out that 2-Brom-LSD, a strong 
82/ 
peripheral antagonist of 5-HT lacks the central actions of LSD-25• 
In another study, these investigators showed, using several deriva¬ 
tives of lysergic acid, that the relative potency of 5-HT antagonism 
84/ 
was unrelated to psychic effect. C-addum and Vogt observed sedation 
and excitement following the intraventricular injection of 5-HT and 
47/ 
LSD-25, respectively. Administered together, LSD-25 and 5-HT produced 
the effects of LSD-25 alone. On the basis of these and electroen- 
cephalographic observations, Vogt et al. concluded that the effects 
of LSD-25 and 5-HT depended upon the action of each drug on separate 
46/ 
receptor sites, and not upon a competition for the same receptors. 
Other neurophysiological investigations have produced conflicting 
38-40,45,85/ 
results. Of note has been the finding of apparent similar 
actions of both compounds on the synaptic potentials of the trans- 
38-40/ 
callosal pathway of the cat's visual svstem, and on diencephalic 
86/ 
temperature regulation. 
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METHODS 
Two basic groups of experiments were included in this work. 
In the first group, the rat was used as the experimental animal}, and 
the whole brain was analyzed for serotonin content. In this way, 
the effect of LSD-25 on total 5-HT content of the brain could be 
determined with variation in several different parameters, The 
second group utilized dogs treated with LSD-25 in order to detect 
more subtle changes in 5-HT content within specific brain areas. 
I. Experiments on 5-HT in Lhole Rat Brain: 
Male albino rats weighing 100-250 grams were used. LSD-25 
was administered intraperitoneally in a dose of 100 micro grams/kilogram. 
In the first experiment, three rats served as controls, while the 
LSD-25 treated rats were sacrificed at various time intervals (0.5,~ 
1, 2, 4, and & hours) following a single LSD-25 injection. The second 
and third experiments involved the daily administration of LSD-25 
over the period of five days. On each day, three LSD-25 treated 
rats were sacrificed at 10 minute and 24 hour intervals following * 
the LSD-25 injection, respectively. Five control rats were included 
in each experiment. The time intervals of 10 minutes and 24 hours 
were chosen as perhaps being the most likely times to detect,5-HT 
changes, since the maximum behavioral effects of LSD-25 in the rat 
76/ 
usually occur in 10-15 minutes, and since tolerance, which occurs 
with daily injections of LSD-25, presumably is preceded by biochemical 
changes in the brain which are present 24 hours after the previous 
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injection. All rats were sacrificed by decapitation. The brains 
(excluding the olfactory bulbs and pituitary glands) were rapidly 
dissected out, weighed and homogenized in 4 ml. of isotonic saline. 
The 5-HT extraction and assay are described below. 
II, Experiments on 5-HT in Specific Areas of the Dog’s Brain: 
For these experiments mongrel dogs of both sexes were used. 
Four dogs served as controls and did not receive LSD-25. The remainder 
were treated with intraperitoneal injections of LSD-25 in doses of 
25 micrograms/kilogram or 50 micrograms/kilogram as noted in the 
results. Two animals received only one LSD-25 injection, three 
received two daily injections, and two were given daily injections 
for four days. Rectal temperature observations were made in the 
latter two animals. The experimental animals were sacrificed 30-60 
minutes after the final injection, at which time the maximum behavioral 
effects of LSD-25 were usually manifested. 
All dogs were sacrificed by exsanguination under light 
chloroform-ethyl chloride anesthesia. The brains were removed and 
the various brain structures were dissected as described below. The 
total time required for removal and dissection of the brain was 45 
minutes to 1 hour. The brain samples were then weighed, homogenized 
in isotonic saline and extracted as described below. 
III. Dissection of the Dog’s Brain: 
The brain areas selected to be assayed for 5-HT content 
were those regions shown by other investigators to contain relatively 
large amounts of 5-HT or those regions whose function would seem to 
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be altered by LSD-25 administration. The dissection of most of the 
brain parts followed clearly-defined anatomical boundaries as outlined 
in Figure 3 . Further description is necessary regarding certain 
areas, however. The "hypothalamus" sample included the mamillary 
bodies and infundibulum but did not include the optic chiasm or 
hypophysis. The "medial thalamus" consisted of a. 1 mm. thickness of 
the medial aspect of the thalamus. The "lateral thalamus" constituted 
the remainder of the thalamus. The "midbrain" included the corpora 
quadrigemina and cerebral peduncles. The amygdala nucleus was 
difficult to visualize anatomic alls'- in its entirety and consequently 
the "amygdala" samples were obtained from only portions of the nuclear 
gray matter underlying the pyriform cortex. 
IV. Extraction and Assay of 5-HT; 
The homogenates of all brain samples were extracted with 
11/ 
95^ acetone according to the method of Amin et al. The 5-HT content 
of the samples was then estimated bv a bioassay procedure using the 
9/ 
heart of Venus mercenaria, The heart was bathed at room temperature 
in artificial sea water containing in grams/liter: NaCl, 23.0; KC1, 
0.65; CaC^, 1.1; MgCl2»6 ^0, 5.0; and NaHCOq, 0.2. To prevent the 
cardiac inhibitory effects of any acetjdL choline which might be 
present in the extracts, benzoquinonium chloride (6 mg./L.) was 
always added to the bathing medium. Standard solutions of 5-HT and 
tissue extracts were added alternately to the bathing medium at about 
2.5 minute intervals and allowed contact with the heart for about 30 
seconds. 5-HT activity of the extracts was estimated from maximal 
effects of each on the contractile force of the clam’s heart. 
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FIGURE 3 
THE DISSECTION OF THE DOG*3 BRAIN * 
(MIDSAGITAL AND DORSAL VIEWS) 
H MB 
KEY 
C— CAUDATE 
H—HYPOTHALAMUS 
HI—HIPPOCAMPUS 
M—MEDULLA 
MB—MIDBRAIN 
0—OCCIPITAL POLAR CORTEX 
P—POSTERIOR SIGMOID CORTEX 
S—SEPTAL REGION 
T—THALAMUS 
TM—MEDIAL THALAMUS 
TL—LATERAL THALAMUS 
* Adapted from Papez, James W. : Comparative Neurology. Norwood, 
Thomas Y. Crowell Company, 1929* pp. 20; 128. 
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RESULTS 
I. Effect of a Single LSD-25 In.jection upon the Amount of 5-HT in 
VJhole Brains of Rats: 
LSD-25 in 100 micrograms/kilogram doses produced only 
slight observable hyperactivity in the rats tested for 5-HT levels; 
measures of behavior were not undertaken. The effect of LSD-25 on 
the content of 5-HT at various time intervals after a single injec¬ 
tion is illustrated in Table 1. The values obtained in the experi¬ 
mental animals do not differ by more than twice the standard deviation 
from the control mean (p>0.05). This indicates that a single injec¬ 
tion of LSD-25 does not produce any statistically significant changes 
in 5-HT content at the time intervals studied. 
II. Effect of Chronic Administration of LSD-25 Upon the Amount of 
5-HT in the whole Brains of Rats: 
The brain levels of 5-HT obtained by sacrificing rats at 
10 minute and 24 hour intervals following daily injections of LSD-25 
are represented in Table 2. The results in both experiments suggest 
a slight depression of 5-HT level after two LSD-25 injections and 
elevations of 5-HT levels after 3, k} or 5 daily injections. These 
values are suggestive of alterations in brain levels of 5-HT but do 
not show significance by the statistical tests employed, 
III. 5-HT Levels in Various Regions of the Untreated LogUs Brain: 
The distribution of 5-HT obtained in the brains of control 
dogs is illustrated in Table 3. The pattern of distribution of 5-HT 
obtained in these experiments is in general agreement with the results 
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TABL5 1 
SEROTONIN (5-HT) LEVELS IN WHOLE BRAINS 
OF RATS FOLLOWING A SINGLE INJECTION OF 
LYSERGIC ACID DIETHYLAMIDE (LSD-25)* 
NUMBER OF TIME OF SACRIFICE 5-HT (NG./GM. OF MEAN 
ANIMALS (HRS. AFTER TREATMENT) BRAIN TISSUE) 
13 POOLED 355; 452; 326; 326; 390; 
CONTROLS 409; 460; 445, 226; 368** 
191; 355; 482; 399 
4 0.5 335; 531; 455; 423 450 
3 1 432; 352; 237 357 
4 2 337; 290; 359; 329 329 
4 4 426; 460; 463; 292 412 
2 3 432; 294 363 
3 24 345; 363; 491 401 
* Dosage of 100 micrograms/kilogram. 
** Standard deviation of the mean—85. 
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TABLE 2 
SEROTONIN (5-HT) LEVELS IN WHOLE BRAINS OF 
RATS AFTER CHRONIC ADMENISTRATION OF 
LYSERGIC ACID DIETHYLAMIDE (LSD-25) (10ljfcfi/Ka) 
EXPERIMENT A * 
NUMBER OF NUMBER OF DAILY 5-HT LEVELS (NG./GM. MEAN 
ANIMALS LSD-25 INJECTIONS OF BRAIN TISSUE 
13 TOOLED 
CONTROLS 
355; 
409; 
191; 
452; 
460; 
355; 
326: 
445; 
482; 
326; 390; 
226; 
399 
368 
3 1 375; 397; 368 380 
3 2 239; 242; 244 242 
3 3 460; 457; 471 463 
3 4 471; 408; 460 446 
3 5 302: 302; 393 332 
EXPERIMENT B ** 
NUMBER OF NUMBER OF DAILY 5-HT LEVELS (NG./GM. MEAN 
ANIMALS LSD-25 INJECTIONS OF BRAIN TISSUE 
13 POOLED 355; 452; 326; 326; 390; 
CONTROLS 409; 460; 445; 226; 368 
191; 355; 482; 379 
3 1 364; 349; 229 314 
3 2 245; 231; 231 236 
3 3 674; 414; 370 486 
3 4 447; 357; 238 347 
3 5 600; 475; 473 519 
*• Rats sacrificed 10 minutes folio-wing the last LSD-25 injection, 
** Rats sacrificed 24 hours folio-wing the last LSD-25 injection. 
S SJgAT 
2 
_- ■ — 
.. \. : r ' - . 
SO y^SMOM 
- 
A 
. 
|3 
pvc isu *^?.e i.i9i 
ex 
;W. t?T 
A.: £ ;£A£ :?££ 
£oA xvA iVclA {Oil £ 
. £ 
14/'- h . 
_ 
a ioch 
?,I 'ST MOO 
: • : ;£$£ ;S*A ;?*£ 
lO-jA : jlfl 
i?A£ ;AA£ 
• ■ 
ove -■ 
e 
esiirniin 01 b^oili'tose et&fi * tiofif.fi' 5 -uej issi ;nJ gniwollc'r. ... . e 
■ 
- 23 - 
TABLE 3 
SEROTONIN (5-HT) LEVELS IN VARIOUS 
PARTS OF THE BRAINS OF CONTROL DOGS 
EXPRESSED AS NG./GM. OF BRAIN TISSUE 
BRAIN AREA 5-HT CONTENT MEAN 
MEDULLA 135; 500; 258; 280 294 
MIDBRAIN 
- ; 2087*; 382; 706 544 
POSTERIOR SIGMOID CORTEX 
- ; - ; 38; 45; 56 46 
OCCIPITAL POLAR CORTEX - ; <25; <20; 28 <28 
SEPTAL REGION 195; 38; 86; 133 126 
HYPOTHALAMUS 909; 652; 244; 833 660 
HIPPOCAMPUS 167; 92; 100; 300 165 
THALAMUS (MEDIAL) 400; 369; 139; 526 353 
THALAMUS (LATERAL) 328; 160; 66; 341 224 
THALAMUS (WHOLE) 303; 169; 112; 341 231 
CAUDATE 244; 214; 145; 283 222 
AMYGDALA 444; 308; 313; 469 384 
Due to a technical error; this result was not averaged with 
the other midbrain values. 
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11-12, 14, 16-1?/ 
of other workers. The largest amounts of the amine 
were concentrated in those structures associated with autonomic func¬ 
tion. This is particularly well demonstrated in the relatively large 
quantity of 5-NT contained in the medial thalamus as compared with 
the lateral thalamus. The highest concentrations of 5-nT were 
usually obtained in the hypothalamus and midbrain while comparatively 
small amounts were detected in the neocortical areas (posterior 
sigmoid cortex and occipita,l polar cortex.) The remaining brain 
areas occupied an intermediate position, 
IV. Effect of Administration of LSD-25 on 5-KT Levels in the Dog's 
Brain: 
The injection of LSD-25 in doses of 25-50 micrograms/kilogram 
produced variable behavioral changes in the dogs used in these 
experiments. No detectable behavioral changes could be noted in 
some of the animals while others showed a marked response which 
consisted of: 1. "perking up" the ears; 2. assuming a fixed stance 
and staring as if out of contact with their surroundings; 3. hyper- 
reacting or hyporeacting to visual and auditory stimuli; and 4» 
salivating excessively. Dilatation of the pupils was observed in 
all dogs following the injection of LSD-25. The response to LSD-25 
usually was maximal by 30 minutes after the injection and subsided 
almost completely by the end of four hours. In the two animals treated 
with 4 daily injections of LSD-25, tolerance was observed to develop 
to the behavioral and pupillary effects of LSD-25 during the course 
of the experiment such that little or no response to the LSD-25 was 
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observable on the fourth day. Rectal temperatures in these two 
animals showed a mean rise of O.S^F, 1.05^F and 0»2^F at 30 minutes, 
60 minutes and 120 minutes after one LSD-25 injection, respectively. 
This LSD-25 induced hyperpyrexia was noted to subside during the four 
days of the experiment. A third dog given 5 daily injections developed 
tolerance to the behavioral and pupillary changes but not to the 
temperature effects. 
The 5-HT levels in the various parts of the brains of dogs 
treated with 1, 2 and 4 daily injections of LSD-25 are tabulated in 
Tables U, 5, and 6, and are summarized in Table 7. There is no change 
in the rank order of the various brain areas with respect to 5-HT 
content in treated and non-treated animals. There is a distinct trend 
toward elevation of brain 5-HT in all of the LSD-25 treated dogs 
as compared with the control animals. This trend is seen in all 
areas but the magnitude of the elevation is most striking in specific 
areas—the midbrain, hypothalamus and amygdala. 
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TABLE 4 
SIROTONIN (5-HT) LEVELS IN VARIOUS PARTS OF 
THE DOG'S BRAIN FOLLOWING A SINGLE INJECTION 
OF LYSERGIC ACID DIETHYLAMIDE (LSD-25) (50AC./KG.) 
BRAIN AREA 5-HT CONTENT* MEAN* 
MEDULLA 417; 463 440 
MIDBRAIN 715; 1035 875 
■POSTERIOR SIGMOID CORTEX 73; 46 60 
OCCIPITAL POLAR CORTEX 24; 29 26 
SEPTAL REGION 92; 200 146 
HYPOTHALAMUS 968; 870 919 
HIPPOCAMPUS 212; 334 273 
THALAMUS (MEDIAL) 435; 750 592 
THALAMUS (LATERAL) 233; 258 246 
CAUDATE 164; 400 282 
AMYGDALA 606; 577 592 
Expressed as ng./gra0 of brain tissue 
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TABLE 5 
SEROTONIN (5-HT) LEVELS IN VARIOUS PARTS OF THE DOG'S BRAIN 
FOLLOWING TWO DAILY INJECTIONS OF LYSERGIC ACID DIETHYLAMIDE 
(EXPRESSED AS NG./GM. OF BRAIN TISSUE) 
BRAIN AREA 5-HT CONTENT 
DOG A* DOGS B AND C** 
MEAN 
MEDULLA 328 382; 26? 326 
MIDBRAIN 800 1176; 826 934 
POSTERIOR SIGMOID CORTEX 10? 49; 33 - 65 
OCCIPITAL POLAR CORTEX 24 42; 32 33 
SEPTAL REGION 250 146; 120 172 
HYPOTHALAMUS 833 62; 1364 753 
HIPPOCAMPUS 182 188; 125 165 
THALAMUS (MEDIAL) 450 643; 300 464 
THALAMUS (LATERAL) 454 100; 2?6 293 
THALAMUS ( WHOLE) 259 247; 302 269 
CAUDATE 522 272; 313 369 
AMYGDALA 534 800; 375 570 
* Dog A received LSD-25 doses of 5Q*g./kg. 
Dogs B and C received LSD-25 doses of 2fj^g./kg. 
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TABLE 6 
5-HT LEVELS IN VARIOUS FARTS OF THE DOG'S 
BRAIN AFTER DAILY ADMINISTRATION OF 
LSD-25 (5Q&G./KG.) FOR FOUR DAIS 
BRAIN AREA 5-HT CONTENT* MEAN 
MEDULLA 236; 63& 437 
MIDBRAIN 674; 1163 918 
POSTERIOR SIGMOID CORTEX 73; 77 75 
OCCIPITAL POLAR. CORTEX 41; 36 38 
SEPTAL REGION 109; 155 132 
HYPOTHALAMUS 750; 813 784 
HIPPOCAMPUS 192; 111 152 
THALAMUS (MEDIAL) 568; 417 502 
THALAMUS (LATERAL.) 179; 164 172 
THALAMUS (WHOLE) - ; 280 280 
CAUDATE 221; 286 254 
AMYGDALA 465; 450 458 
■55- Expressed as ng./gnu of brain tissue 
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TABLE 7 
SUMMARY OF MEM $-HT LEVELS OF THE DOG’S BRAIN 
FOLLOWING CHRONIC DAILY ADMINISTRATION OF LSD-25 
(EXPRESSED IN NG./GM. OF BRAIN TISSUE) 
BRAIN AREA 5-HT CONTENT 
1 
CONTROL INJECTION 
2 
INJECTIONS 
4 
INJECTIONS 
MEDULLA 294 440 326 437 
MIDBRAIN 544 875 934 918 
POSTERIOR SIGMOID CORTEX 46 60 65 75 
OCCIPITAL POLAR CORTEX 26 33 38 
SEPTAL REGION 126 146 172 132 
HYPOTHALAMUS 660 919 753 784 
HIPPOCAMPUS 165 273 165 152 
THALAMUS (MEDIAL) 358 592 464 502 
THALAMUS (LATERAL) 224 246 293 1?2 
THALAMUS (WHOLE) 231 - 269 280 
CAUDATE 222 282 369 254 
AMYGDALA 384 592 570 458 
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DISCUSSION 
The results would tend to indicate that no significant 
alterations of 5-HT levels in the whole rat brain occur at the time 
intervals studied following a single LSD-25 injection. This is in 
agreement with the results obtained by other workers examining the 
w 
brains 4 hours after injection. The experiments involving the 
chronic administration of LSD-25 to rats su;gest slight changes in 
5-HT brain content but the results are not statistically conclusive. 
Similarly slight, elevations of 5-HT values were observed generally 
throughout the areas of the dog's brain following acute and chronic 
administration of LSD-25. The significance of these slight changes 
cannot be stated. Certainly, they are not as dramatic as the 2-3 
fold increases in brain 5-HT obtained in this laboratory following 
87/ 
iproniazid ("Marsalid") administration. 
Certain speciJfic details of the experimental method must 
be considered in evaluating the above results. The possibility exists 
that changes in the distribution or quantity of 5-HT occurred after 
sacrifice. However, the tissues were kept cold with ice, and the 
dissection proceded in the same order for each experiment. The 
chloroform-ethyl chloride might have influenced the 5-HT levels in 
the dog experiments to some degree, although presumably the effect 
of the anesthesia would be constant for the control and experimental 
animals. It is unlikely that LSD-25 retained in the tissue extracts 
directly altered the response of the heart of Venus mercenaria in 
the 5-HT assay since the phenomenon of irreversible stimulation of 
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32/ 
the heart by LSD-25, described by Welsh, was not observed following 
treatment with any of the extracts. 
It must be noted that the techniques utilized in these 
experiments do not allow one to generalize upon the results obtained* 
the findings at the times of sacrifice after LSD-25 administration, 
which were selected, do not necessarily bear any resemblance to results 
which might be obtained at other times. Similarly, the doses of LSD-25 
which were utilized might not be optimal for demonstrating neuro- 
chemical changes. Significant redistribution of 5-HT might have oc¬ 
curred in brain areas which were not selected for analysis in this 
study. Moreover, redistribution of 5-HT following LSD-25 administra¬ 
tion could occur on an intracellular level and escape detection. 
Negative findings in a work of this kind do not exclude 
the possibility that LSD-25 acts centrally through a mechanism 
involving 5-HT. Such an action could take place without changes 
in 5-HT concentrations occurring in the brain which would be 
observable by the techniques employed. 
On the other hand, the observation of alterations of 5-HT 
following LSD-25 administration, as suggested in the experiments 
using the dog’s brain, imply a possible biochemical correlation 
with the activity and tolerance which follows LSD-25. Such a 
correlation cannot be established on the basis of present findings, 
but requires additional information concerning: 1. The interaction 
of LSD-25 with various chemical systems existing in the brain and 
5-HT in particular; 2. neural receptor phenomena; 3« the neuro- 
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pharmacological actions of 5-HT; and 4, the relation of neural, 
changes to behavior. Of these lines of investigation, the study of 
neurochemical systems appears to be the most promising at the moment. 
A great deal has been learned about the effect of certain compounds 
on the binding of 5-KT and on the enzymes concerned in its synthesis 
and destruction. The manner in which LSD-25 is involved in these 
processes, however, remains a problem for future investigation. 
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SUMMARY 
Brain levels of 5-hydroxytryptanine (5-KT) were studied 
in rats at different time intervals following acute and chronic 
administration of lysergic acid diethylamide (LSD-25). No signifi¬ 
cant alterations of 5-HT content were noted at various times 
following a single LSD-25 injection. With chronic administration, 
a trend toward depression of brain 5-KT content after the second 
daily injection and slight elevation after the third, fourth, and 
fifth daily injections was observed. 
In dogs, an unequal distribution of 5-KT within the brain 
was observed. No striking changes in 5-KT levels occurred following 
administration of LSD-25, with the possible exceptions of the 
midbrain, hypothalamus and amygdala, though the levels of all of 
the brain areas studied appeared to be slightly greater than the 
controls 
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